文献速递脑血管病外科神经重症

持续性动脉内尼莫地平治疗难治性迟发性脑缺血:反应不足与不良预后的相关因素

Continuous Intra-arterial Nimodipine Therapy in SAH Patients With Refractory DCI-Factors Associated With Insufficient Response and Unfavorable Outcome.
PubMed 文献 · World Neurosurg · 2026-07-30

该回顾性研究分析2016-2023年36例动脉瘤性蛛网膜下腔出血后难治性迟发性脑缺血接受持续性动脉内尼莫地平输注(CIAN)的患者,定义充分反应为血管管径恢复>75%且灌注改善。44%患者反应充分,56%反应不足;反应不足与更高WFNS和mFS评分、多发动脉瘤及弥漫性血管痉挛相关,并更多伴随DCI相关梗死和不良预后,但可能反映严重血管痉挛生物学而非独立治疗效应。

要点

  • CIAN是难治性DCI可行的血管内挽救策略,但停药后复发常见(39%)。
  • 反应不足与更高WFNS、mFS、多发动脉瘤和弥漫性血管痉挛聚集出现。
  • 反应不足伴随更多DCI相关梗死和6个月不良预后,但可能反映基线严重程度。

核心结论

  • CIAN在部分难治性DCI患者中可行,但复发常见,反应不足与严重疾病标志物聚集并关联不良预后。
  • 反应不足可能反映严重潜在血管痉挛生物学而非独立治疗效应,需前瞻性研究验证。

研究设计与样本

  • 回顾性分析2016-2023年接受CIAN的aSAH患者,微导管置于颈内动脉或椎动脉。
  • 共纳入36例患者,平均年龄53±12岁,75%为女性。

主要发现

  • 16例(44%)反应充分,20例(56%)反应不足。
  • 停药后复发14例(39%),7例(19%)需重复CIAN。
  • 反应不足与更高WFNS和mFS评分、多发动脉瘤及弥漫性血管痉挛相关。
  • 反应不足更多伴随DCI相关梗死和不良预后,但重叠于基线严重度标志物。
  • 操作相关并发症不常见,且与梗死或预后恶化无关。

关键数值与推荐

  • 充分反应定义为基线血管管径恢复>75%且灌注改善。

临床怎么用

  • CIAN可用于经诱导高血压和间歇动脉内尼莫地平治疗无效的影像确认血管痉挛伴灌注缺损的aSAH患者。
  • 对高WFNS、高mFS、多发动脉瘤或弥漫性血管痉挛者,应预期反应不足和不良预后风险较高。

局限性

  • 回顾性设计,样本量36例,结论为假设生成性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous intra-arterial nimodipine infusion (CIAN) is an endovascular rescue therapy for refractory delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH). Response and recurrence remain incompletely characterized. METHODS: We retrospectively analyzed aSAH patients treated with CIAN (2016-2023) for imaging-confirmed vasospasm with perfusion deficits refractory to induced hypertension and intermittent intra-arterial nimodipine; microcatheters were placed in internal carotid or vertebral arteries. Analyzed variables included clinical characteristics, aneurysm parameters, WFNS, modified Fisher score (mFS), treatment response, vasospasm recurrence, DCI-associated infarctions, CSF diversion, and 6-month modified Rankin Scale (mRS). Sufficient response was defined as >75% restoration of baseline vessel caliber with perfusion improvement. RESULTS: Of 36 patients (mean age 53 ± 12 years; 75% female), 16 (44%) responded sufficiently and 20 (56%) insufficiently. Recurrence after discontinuation occurred in 14 (39%); 7 (19%) required repeat CIAN. Insufficient response was associated with higher WFNS and mFS, multiple aneurysms, and generalized vasospasm. Insufficient response co-occurred with more DCI-related infarctions and unfavorable outcome but, given the overlap with baseline severity markers, likely reflects severe underlying vasospasm biology rather than an independent therapeutic effect. Procedure-related complications were uncommon and not associated with infarction or outcome deterioration. CONCLUSIONS: CIAN is a feasible endovascular rescue strategy in selected patients with refractory DCI, although recurrence was common. Insufficient response clustered with markers of severe disease-higher WFNS and mFS, younger age, multiple aneurysms, generalized vasospasm-and was associated with unfavorable outcome. This study generates hypotheses for prospective studies.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Kurz E, Kalasauskas D, Ringel F, et al. Continuous Intra-arterial Nimodipine Therapy in SAH Patients With Refractory DCI-Factors Associated With Insufficient Response and Unfavorable Outcome. World Neurosurg. 2026. PMID: 42532187. doi:10.1016/j.wneu.2026.125216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。